Matches 1 - 50 out of 161 1 2 3 4 >


Match Document Document Title
US20110150986 QUININE FORMULATIONS, METHOD OF MAKING, AND METHO OF USE THEREOF  
Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or...
US20110268797 MULTICOATED ALISKIREN FORMULATIONS  
An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers.
US20130115286 ORAL ADMINISTRATION FORMS FOR CONTROLLED RELEASE OF RIFAMPICIN FOR THE TREATMENT OF BACTERIAL INFECTIONS AND INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT  
Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for...
US20110150992 QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF  
Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or...
US20130059000 ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS  
A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three...
US20110033528 STABILIZED PICOPLATIN ORAL DOSAGE FORM  
The invention provides an oral dosage form for the anti-cancer drug picoplatin comprising a core and a coating, the dosage form being free of redox-active metal salts. The core of the tablet is a...
US20120189693 ORAL DOSAGE FORMS  
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0...
US20110287100 Galenic Formulations of Organic Compounds  
A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount...
US20140370092 FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE  
Pharmaceutical compositions and single unit dosage forms of apremilast, i.e., (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 -acetylaminoisoindoline-1,3-dione, or a pharmaceutically...
US20110081412 ORALLY DISINTEGRABLE TABLETS  
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated...
US20110300217 HYDROMORPHONE THERAPY  
A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
US20150056281 Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta  
This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an...
US20150056275 CONTROLLED-RELEASE SOLID DOSAGE FORMS OF MESALAMINE  
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of...
US20150037407 METHOD TO IMPROVE THE SAFETY OF HANDLING OF HIGH POTENCY DRUGS IN SOLID DOSAGE FORMS WITHOUT CHANGING THEIR EFFICACY  
A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy...
US20130251804 METHOD TO IMPROVE THE SAFETY OF HANDLING OF HIGH POTENCY DRUGS IN SOLID DOSAGE FORMS WITHOUT CHANGING THEIR EFFICACY  
A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy...
US20150246043 ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB  
The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms.
US20130243858 COMPOUND FORMULATIONS  
Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The...
US20100226855 Rate-Controlled Oral Dosage Formulations  
The present invention relates to a drug delivery system, in which a drug containing core, either alone or coated with a rate controlling membrane system, is enveloped on its circumference by an...
US20150037263 TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD  
This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an...
US20120064162 DRY-COATED ORALLY-DISINTEGRATING TABLET  
The purpose of the present invention is to provide a press-coated orally-disintegrating tablet characterized by containing an inner core which has an excellent disintegratability in oral cavity...
US20140178469 STABLE BENZIMIDAZOLE FORMULATION  
A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile...
US20140056973 Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug  
Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.
US20140212492 Oral Enzyme Compositions for Intestinal Delivery  
The present disclosure describes compositions for intestinal delivery of enzyme formulations and methods of treating health problems with these formulations. More specifically, the enzyme...
US20130084333 ABUSE RESISTANT ORAL DOSAGE FORMS  
Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the...
US20150132378 MULTILAYERED DOSAGE FORM  
The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active...
US20130011479 DOUBLE-LAYER PHARMACEUTICAL FORMULATIONS CONTAINING OPIOID AGONISTS AND ANTAGONISTS  
Immediate-release formulations are described, consisting of double-layer tablets wherein one layers contains an opioid agonist and the other an opioid antagonist.
US20130202696 Agent for use in the case of fructose intolerance  
There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose...
US20130202694 Agent for use in the case of fructose intolerance  
There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose...
US20140127299 GRAS Enteric Coating Formulations and Methods of Making and Using Same  
Disclosed herein are food-grade enteric coating compositions designed to release pharmaceutical and/or nutraceutical products at various regions of the intestines, wherein said compositions...
US20120177739 Delayed Release Tablet with Defined Core Geometry  
A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85...
US20110097399 FAST DISSOLVING/DISINTEGRATING COATING COMPOSITIONS  
A pharmaceutical composition for oral administration comprising a core and a film coating on the core that exhibits enhanced disintegration characteristics is disclosed. The film coating comprises...
US20100310655 Crystal modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof  
The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal...
US20140328914 TALC-FREE POLYVINYL ALCOHOL COMPOSITION  
The present invention provides a talc-free composition characterizable as non-tacky and having an average water vapor permeability of at most 5.0 times 10−7 grams per Pascal-hour-meter and having...
US20110165241 BAZEDOXIFENE FORMULATIONS WITH ANTIOXIDANTS  
This disclosure relates to pharmaceutical compositions comprising bazedoxifene and an antioxidant such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, or BHA/BHT, substantially free of...
US20130129825 DIVERSION-RESISTANT MICROGRANULES AND MICROTABLETS  
The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the...
US20120064161 MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS  
Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin.
US20110182987 PHARMACEUTICAL DOSAGE FORM FOR THE SITE-SPECIFIC DELIVERY OF MORE THAN ONE ACTIVE PHARMACEUTICAL INGREDIENT  
This invention relates to a pharmaceutical dosage form for the site specific delivery of more than one active pharmaceutical ingredient to different sites in the human or animal body in the...
US20130243861 PRESS-COATED TABLETS OF PREDNISONE  
The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness...
US20080057125 STABLE TABLET DOSAGE FORMS OF PROTON PUMP INHIBITORS  
This invention relates to a method of making oral formulations of practically water insoluble, or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of...
US20110104277 OXYGEN BARRIER FILM COATINGS FOR PHARMACEUTICAL DOSAGE FORMS  
A film coating which is an oxygen barrier is applied to a pharmaceutical dosage form to protect the dosage form from atmospheric oxygen. The coating comprises a polymeric binder, an...
US20110311619 PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE  
The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.
US20120156296 ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS  
This invention relates to antioxidants and combinations of antioxidants used to prevent oxidation of pharmaceutical and nutraceutical products in the form of powders, granulates, tablets,...
US20130315995 DIRECT COMPRESSION POLYMER TABLET CORE  
The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of...
US20120321711 DIRECT COMPRESSION POLYMER TABLET CORE  
The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of...
US20130344150 DIRECT COMPRESSION TABLETS OF OTILONIUM  
This invention is related to direct compression of otilonium or its pharmaceutically acceptable salt having perfect powder flowability, good tablet weight distribution and no sticking to the punches.
US20140335174 DRY-COATED TABLET CONTAINING TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM  
The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell.
US20150079171 EASILY ADMINISTRABLE SOLID PREPARATION  
It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable...
US20090252794 TABLET  
The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by...
US20070269515 Probiotic Tablet Formulations  
A probiotic tablet comprising a probiotic micro-organism and other nutritionally active ingredients in two zones, a first zone comprising said probiotic micro-organism and prcicrably selenium, and...
US20150093439 COMPRESSION COATED PULSATILE RELEASE COMPOSITIONS  
The present invention is directed to a dosage form comprising an immediate release portion of a first active pharmaceutical ingredient and a delayed release portion of a second active...

Matches 1 - 50 out of 161 1 2 3 4 >